Oxford BioDynamics Plc (LON: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry,..
Oxford BioDynamics Plc (LON: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry,..
Oxford Biodynamics PLC (LON:OBD) Chief Executive Officer Christian Hoyer Millar caught up with DirectorsTalk for an exclusive interview to discuss their fifth collaboration agreement. Q1: Another collaboration agreement this..
Oxford BioDynamics enters into collaboration to identify EpiSwitch™ biomarkers for the diagnosis of Autism Spectrum Disorder (ASD) · Diagnosis of ASD is challenging, indicating the need for accurate diagnostic biomarkers...
Oxford BioDynamics plc (LON:OBD) CEO Christian Hoyer Millar joins DirectorsTalk to discuss contract number 5 in the Immuno Oncology space. Christian also discusses proprietary IP and the increased capacity to..
Oxford BioDynamics Plc (LON:OBD) has today announced that it has entered into its fifth collaboration agreement for the development of predictive biomarkers for immuno-oncology (IO) therapeutics. · Agreement with major..
Study published in Faculty of 1000 Research identifies epigenetic changes for monitoring disease progression in Huntington’s disease (HD) There is a high clinical need for a molecular tool to assess..
Oxford BioDynamics Plc (LON:OBD) has today announced that it has been chosen as an industrial partner in a Horizon 2020 international research and innovation collaboration. The initiative on “Predictive Epigenetics”..
Oxford Biodynamics PLC (LON:OBD) Chief Executive Officer Christian Hoyer Millar caught up with DirectorsTalk for an exclusive interview to discuss GL Capital’s stake in the company. Q1: This morning..
Oxford BioDynamics Plc (LON:OBD) CEO Christian Hoyer Millar talks to DirectorsTalk about with its co-operation agreement with GL Capital Group to address the growing demand for healthcare and personalised medicine..
Oxford BioDynamics Plc (LON:OBD) announced today that it has entered into a Co-operation Agreement with GL Capital Group to address the growing demand for healthcare and personalised medicine in China...
Oxford Biodynamics PLC (LON:OBD) Chief Scientific Officer Dr Alexandre Akoulitchev caught up with DirectorsTalk for an exclusive interview to discuss their recent work published at the Summit on Emerging Immunotherapies..
Oxford Biodynamics Plc (LON:OBD) CSO Dr Alexandre Akoulitchev talks to DirectorsTalk about presenting its work in Washington at the Summit on Emerging Immunotherapies for Hematologic Diseases. Alexandre describes for us..
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today..
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has..
Oxford Biodynamics PLC (LON:OBD) Chief Scientific Officer Dr Alexandre Akoulitchev caught up with DirectorsTalk for an exclusive interview to discuss their recent publication in EBioMedicine, more about the biomarkers and..
Oxford BioDynamics Plc (LON:OBD) CSO Dr Alexandre Akoulitchev explains to DirectorsTalk how the OBD work on ALS published in EBioMedicine fits into the bigger picture around this disease, the nature..
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has..
Oxford Biodynamics PLC (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today..
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, expects..
